David A. Richards

David A. Richards

Auto-generated profile, based on publicly available information

David A. Richards

Department of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen, Norway

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2007 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
SGSimon Gilbody
Simon Gilbody
DRDavid Richards
David Richards
SBStephen Brealey
Stephen Brealey
CHCatherine Hewitt
Catherine Hewitt

27 November 2006 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
SGSimon Gilbody
Simon Gilbody
PBPeter Bower
Peter Bower
JFJanine Fletcher
Janine Fletcher
DRDavid Richards
David Richards
ASAlex J. Sutton
Alex J. Sutton
Depression is soon to become the second leading cause of disability worldwide.1 It affects between 5% and 10% of individuals and is the third most common reason for consultation in primary care.2 Management falls below accepted evidence-based standards,3,4 and the enhanced management of depression in primary care is central to the World Health Organization strategy for mental health.5 Many organizational and educational strategies targeted at health care professionals have been proposed to improve the recognition and management of depression in primary care.6 These include the following: educational strategies, such as guidelines, targeted at health care professionals7; consultation-liaison, with an educative role for practitioners working more closely with nonspecialist clinicians8; and collaborative care involving a structured approach to care based on chronic disease management principles and a greater role for nonmedical specialists such as nurse practitioners working in conjunction with the primary care physician and a mental health specialist.9

17 October 2012 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
JAJanine Archer
Janine Archer
PBPeter Bower
Peter Bower
SGSimon Gilbody
Simon Gilbody
KLKarina Lovell
Karina Lovell
DRDavid Richards
David Richards
Peter CoventryPeter Coventry
Peter Coventry

1 February 2007 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
JBJonathan I. Bisson
Jonathan I. Bisson
AEAnke Ehlers
Anke Ehlers
RMRosa Matthews
Rosa Matthews
SPStephen Pilling
Stephen Pilling
DRDavid Richards
David Richards
STStuart Turner
Stuart Turner
Background: The relative efficacy of different psychological treatments for chronic post-traumatic stress disorder (PTSD) is unclear.Aims: To determine the efficacy of specific psychological treatments for chronic PTSD.Method: In a systematic review of randomised controlled trials, eligible studies were assessed against methodological qualitycriteria and data were extracted and analysed.Results: Thirty-eight randomised controlled trials were included in the meta-analysis. Trauma-focused cognitive-behavioural therapy (TFCBT), eye movement desensitisation and reprocessing (EMDR), stress management and group cognitive-behavioural therapy improved PTSD symptoms more than waiting-list or usual care. There was inconclusive evidence regarding other therapies. There was no evidence of a difference in efficacy between TFCBT and EMDR butthere was some evidence that TFCBT and EMDR were superior to stress management and other therapies, and that stress management was superior to other therapies.Conclusions: The first-line psychological treatment for PTSD should be trauma-focused (TFCBTor EMDR).

1 August 2016 in The Lancet
Verified
Journal Article
Open access
DRDavid A Richards
David A Richards
DEDavid Ekers
David Ekers
DMDean McMillan
Dean McMillan
RTRod S Taylor
Rod S Taylor
SBSarah Byford
Sarah Byford
KFKatie Finning
Katie Finning
Depression is a common, debilitating, and costly disorder. Many patients request psychological therapy, but the best-evidenced therapy-cognitive behavioural therapy (CBT)-is complex and costly. A simpler therapy-behavioural activation (BA)-might be as effective and cheaper than is CBT. We aimed to establish the clinical efficacy and cost-effectiveness of BA compared with CBT for adults with depression. In this randomised, controlled, non-inferiority trial, we recruited adults aged 18 years or older meeting Diagnostic and Statistical Manual of Mental Disorders IV criteria for major depressive disorder from primary care and psychological therapy services in Devon, Durham, and Leeds (UK). We excluded people who were receiving psychological therapy, were alcohol or drug dependent, were acutely suicidal or had attempted suicide in the previous 2 months, or were cognitively impaired, or who had bipolar disorder or psychosis or psychotic symptoms. We randomly assigned participants (1:1) remotely using computer-generated allocation (minimisation used; stratified by depression severity [Patient Health Questionnaire 9 (PHQ-9) score of <19 vs ≥19], antidepressant use, and recruitment site) to BA from junior mental health workers or CBT from psychological therapists. Randomisation done at the Peninsula Clinical Trials Unit was concealed from investigators. Treatment was given open label, but outcome assessors were masked. The primary outcome was depression symptoms according to the PHQ-9 at 12 months. We analysed all those who were randomly allocated and had complete data (modified intention to treat [mITT]) and also all those who were randomly allocated, had complete data, and received at least eight treatment sessions (per protocol [PP]). We analysed safety in the mITT population. The non-inferiority margin was 1·9 PHQ-9 points. This trial is registered with the ISCRTN registry, number ISRCTN27473954. Between Sept 26, 2012, and April 3, 2014, we randomly allocated 221 (50%) participants to BA and 219 (50%) to CBT. 175 (79%) participants were assessable for the primary outcome in the mITT population in the BA group compared with 189 (86%) in the CBT group, whereas 135 (61%) were assessable in the PP population in the BA group compared with 151 (69%) in the CBT group. BA was non-inferior to CBT (mITT: CBT 8·4 PHQ-9 points [SD 7·5], BA 8·4 PHQ-9 points [7·0], mean difference 0·1 PHQ-9 points [95% CI -1·3 to 1·5], p=0·89; PP: CBT 7·9 PHQ-9 points [7·3]; BA 7·8 [6·5], mean difference 0·0 PHQ-9 points [-1·5 to 1·6], p=0·99). Two (1%) non-trial-related deaths (one [1%] multidrug toxicity in the BA group and one [1%] cancer in the CBT group) and 15 depression-related, but not treatment-related, serious adverse events (three in the BA group and 12 in the CBT group) occurred in three [2%] participants in the BA group (two [1%] patients who overdosed and one [1%] who self-harmed) and eight (4%) participants in the CBT group (seven [4%] who overdosed and one [1%] who self-harmed). We found that BA, a simpler psychological treatment than CBT, can be delivered by junior mental health workers with less intensive and costly training, with no lesser effect than CBT. Effective psychological therapy for depression can be delivered without the need for costly and highly trained professionals. National Institute for Health Research.

17 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DEDavid Ekers
David Ekers
LWLisa Webster
Lisa Webster
ASAnnemieke Van Straten
Annemieke Van Straten
PCPim Cuijpers
Pim Cuijpers
DRDavid Richards
David Richards
SGSimon Gilbody
Simon Gilbody
Depression is a common, disabling condition for which psychological treatments are recommended. Behavioural activation has attracted increased interest in recent years. It has been over 5 years since our meta-analyses summarised the evidence supporting and this systematic review updates those findings and examines moderators of treatment effect. Randomised trials of behavioural activation for depression versus controls or anti-depressant medication were identified using electronic database searches, previous reviews and reference lists. Data on symptom level and study level moderators were extracted and analysed using meta-analysis, sub-group analysis and meta-regression respectively. Twenty six randomised controlled trials including 1524 subjects were included in this meta-analysis. A random effects meta-analysis of symptom level post treatment showed behavioural activation to be superior to controls (SMD −0.74 CI −0.91 to −0.56, k = 25, N = 1088) and medication (SMD −0.42 CI −0.83 to-0.00, k = 4, N = 283). Study quality was low in the majority of studies and follow- up time periods short. There was no indication of publication bias and subgroup analysis showed limited association between moderators and effect size. The results in this meta-analysis support and strengthen the evidence base indicating Behavioural Activation is an effective treatment for depression. Further high quality research with longer term follow-up is needed to strengthen the evidence base.